Metals and metal compounds in cancer treatment
- PMID: 15274320
Metals and metal compounds in cancer treatment
Abstract
Metals and metal compounds have been used in medicine for several thousands of years. In this review we summarized the anti-cancer activities of the ten most active metals: arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium and platinum. The first reviewed metal, arsenic, presents the anomaly of displaying anti-cancer and oncogenic properties simultaneously. Some antimony derivatives, such as Sb2O3, salt (tartrate) and organic compounds, show interesting results. Bismuth directly affects Helicobacter pylori and gastric lymphoma; the effects of bismuth complexes of 6-mercaptopurine are promising. Gold(I) and (III) compounds show anti-tumour activities, although toxicity remains high. Research into the potential use of gold derivatives is still ongoing. Several derivatives of vanadium show anti-proliferative activity, but their toxicity must be overcome. Several pieces of evidence indicate that iron deprivation could be an excellent therapeutic approach; furthermore, it is synergistic with classic anti-cancer drugs. Rhodium belongs to the same group as platinum and it also presents interesting activity, but with the same nephrotoxicity. Several rhodium compounds have entered phase I clinical trials. In contrast to the platinum complexes, titanium derivatives showed no evidence of nephrotoxicity or myelotoxicity; titanocene dichloride is undergoing clinical trial. The anti-proliferative effect of gallium could be related to its competition with the iron atom; in addition a derivative appears to reverse the multidrug resistance. The last metal reviewed, platinum, has given some of the very best anti-cancer drugs. Four derivatives are used today in the clinic; their mechanism of action and of resistance are described.
Similar articles
-
Non platinum metal complexes as anti-cancer drugs.Arch Pharm (Weinheim). 2007 Mar;340(3):117-26. doi: 10.1002/ardp.200600151. Arch Pharm (Weinheim). 2007. PMID: 17315259 Review.
-
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.Drug Resist Updat. 2006 Jun;9(3):111-22. doi: 10.1016/j.drup.2006.05.002. Epub 2006 Jun 21. Drug Resist Updat. 2006. PMID: 16790363 Review.
-
Complexes of metals other than platinum as antitumour agents.Eur J Clin Pharmacol. 1994;47(1):1-16. doi: 10.1007/BF00193472. Eur J Clin Pharmacol. 1994. PMID: 7988618 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Metals and metal derivatives in medicine.Mini Rev Med Chem. 2013 Feb;13(2):211-21. Mini Rev Med Chem. 2013. PMID: 23438056 Review.
Cited by
-
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.Genes (Basel). 2023 Nov 13;14(11):2073. doi: 10.3390/genes14112073. Genes (Basel). 2023. PMID: 38003016 Free PMC article.
-
Toxic Kidney Damage in Rats Following Subchronic Intraperitoneal Exposure to Element Oxide Nanoparticles.Toxics. 2023 Sep 19;11(9):791. doi: 10.3390/toxics11090791. Toxics. 2023. PMID: 37755801 Free PMC article.
-
Metallo-Drugs in Cancer Therapy: Past, Present and Future.Molecules. 2022 Oct 1;27(19):6485. doi: 10.3390/molecules27196485. Molecules. 2022. PMID: 36235023 Free PMC article. Review.
-
Electrospun Membranes Designed for Burst Release of New Gold-Complexes Inducing Apoptosis of Melanoma Cells.Int J Mol Sci. 2022 Jun 27;23(13):7147. doi: 10.3390/ijms23137147. Int J Mol Sci. 2022. PMID: 35806152 Free PMC article.
-
Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.Pharmaceutics. 2022 Mar 30;14(4):743. doi: 10.3390/pharmaceutics14040743. Pharmaceutics. 2022. PMID: 35456577 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
